**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 40496

**Manuscript Type:** MINIREVIEWS

**Conversion surgery for gastric cancer patients: A review**

Zurleni T *et al.* Conversion surgery for gastric cancer

Tommaso Zurleni, Elson Gjoni, Michele Altomare, Stefano Rausei

**Tommaso Zurleni, Elson Gjoni, Michele Altomare, Stefano Rausei**,Department of Surgery, ASST Valle Olona, Busto Arsizio 21052, Italy

**ORCID number:** Tommaso Zurleni ([0000-0002-3971-2297](http://orcid.org/0000-0002-3971-2297)); Elson Gjoni ([0000-0002-5271-2777](http://orcid.org/0000-0002-5271-2777)); Michele Altomare ([0000-0002-3879-2678](http://orcid.org/0000-0002-3879-2678)); Stefano Rausei ([0000-0002-6676-2935](http://orcid.org/0000-0002-6676-2935)).

**Author contributions:** Zurleni T and Rausei S designed the study, edited and revised the manuscript; Zurleni T, Gjoni E and Altomare M reviewed the literature and drafted the study; all authors equally contributed to this paper for the final approval of the final version.

**Conflict-of-interest statement:** All authors stated they have no conflicts of interest to disclose.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to:** **Tommaso Zurleni, MD, Doctor, Surgeon,** Department of Surgery, ASST Valle Olona, Piazzale Solaro 3, Busto Arsizio 21052, Italy. tzurleni@yahoo.it

**Telephone:** +39-331-699716

**Received:** June 27, 2018

**Peer-review started:** July 1, 2018

**First decision:** July 17, 2018

**Revised:** September 25, 2018

**Accepted:** October 7, 2018

**Article in press:**

**Published online:**

**Abstract**

Gastric cancer (GC) is the third most common cancer-related cause of death worldwide. In locally advanced tumors, neoadjuvant chemotherapy has recently been introduced in most international Western guidelines. For metastatic and unresectable disease, there is still debate regarding correct management and the role of surgery. The standard approach for stage IV GC is palliative chemotherapy. Over the last decade, an increasing number of M1 patients who responded to palliative regimens of induction chemotherapy have been subsequently undergone surgery with curative intent. The objective of the present review is to analyze the literature regarding this approach, known as “conversion surgery”, which has become one of the most commonly adopted therapeutic options. It is defined as a treatment aiming at an R0 resection after chemotherapy in initially unresectable tumors. The 13 retrospective studies analyzed, with a total of 411 patients treated with conversion therapy, clearly show that even if standardization of unresectable and metastatic criteria, post-chemotherapy resectability evaluation and timing of surgery has not yet been established, an R0 surgery after induction chemotherapy with partial or complete response seems to offer superior survival results than chemotherapy alone. Additional larger sample-size randomized control trials are needed to identify subgroups of well-stratified patients who could benefit from this multimodal approach.

**Key words:** Gastric cancer; Conversion surgery; R0 resection; Stage IV gastric cancer; Palliative chemotherapy; Unresectable gastric cancer; Metastatic gastric cancer

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Conversion surgery is defined as a surgical treatment with the goal of R0 resection in initially unresectable gastric cancer patients after response to chemotherapy. Although the heterogeneity of metastatic disease factors makes it difficult to identify true prognostic variables, a survival benefit has been demonstrated in several reports.Further prospective large-scale studies seem to be necessary to improve patient selection and to validate this promising multimodal therapy.

Zurleni T, Gjoni E, Altomare M, Rausei S. Conversion surgery for gastric cancer patients: A review. *World J Gastrointest Oncol* 2018; In press

**INTRODUCTION**

Gastric cancer (GC) is known to be the third most common cancer-related cause of death worldwide[1]. Surgical treatment with adequate extended lymphadenectomy is associated with good outcomes in early stages. However, in advanced GC, prognosis remains poor. Neoadjuvant chemotherapy (NAC) has been suggested for resectable, locally advanced GC based on well-known Randomized Controlled Trial (RCT)s[2,3]. Despite many enrolled patients having lower esophagus or esophagogastric junction involvement and surgery not always including a standard extended lymphadenectomy, there was a survival advantage of NAC plus surgery compared to surgery alone. Therefore, NAC, or preferably preoperative chemotherapy, has been recently introduced as an option in most treatment guidelines[4-9].

The SEER database shows that one third of Western patients with GC have unresectable disease, and different strategies have recently been adopted to manage advanced unresectable cancer[10]. Generally, in these cases, surgery is upfront considered as a palliative treatment for obstruction or bleeding.

Palliative chemotherapy remains the main treatment strategy of IV stage GC patients[11]. Although the median survival time (MST) of these patients has improved due to development of new chemotherapeutics agents, it is still unsatisfactory. Therefore, patients who demonstrated a response to chemotherapy have begun to be subsequently surgically treated with curative intent. This approach in stage IV patients, called “conversion surgery”, is becoming one of the most common therapeutic options discussed in the literature over the last decades. The aim of the present review was to define the effective usefulness of this strategy, to identify its crucial aspects and to highlight critical issues and implications for future perspectives.

***Literature search***

We analyzed articles published in English from 1997 to 2017 using the following key words: Conversion surgery, conversion therapy, R0 resection stage IV GC, unresectable GC. We excluded case reports and case series, ultimately obtaining 13 articles for 13 studies. We first analyzed stage IV factors singularly to define major current therapeutic strategies for any selected patient, and then, we considered oncological outcomes of palliative chemotherapy through experiences derived from several trials. Therefore, we focused on the emerging role of conversion therapy as a new treatment option for metastatic gastric cancer patients.

**STAGE IV GC**

Stage IV GC is a heterogeneous biological condition with a mixture of distant metastases, including hematologic, lymph nodal and/or peritoneal. To reduce this heterogeneity, the Japanese Gastric Cancer Association (JGCA) and the Union Internationale Contre le Cancer (UICC) minimized differences between their classifications and categorized similar groups[12-16]. However, these systems do not seem sufficient to derive any significant clinical suggestions.

In the recent classification introduced by Yoshida *et al*[17] with the proposal to identify objective principles for conversion surgery, stage IV patients were subdivided into 4 new categories (Figure 1). Initially, the presence of macroscopic peritoneal dissemination is considered as a different biological and prognostic finding compared with hematological metastases. Patients without peritoneal involvement belong to category 1 (potentially resectable metastases) and category 2 (marginally resectable metastases). Patients with macroscopic peritoneal metastases are stratified into category 3 (unresectable except certain situations) and category 4 (incurable metastases). Below we highlight different critical aspects in terms of staging, treatment and prognosis of different potential metastatic patterns in stage IV GC.

***Peritoneal metastases***

Synchronous peritoneal carcinomatosis (PC) is the most frequent site of metastasis in stage IV GC. PC occurs in 14%-43% of GC patients and represents 35% of all synchronous metastases[18,19]. The prognosis of PC in GC is worse than that for other metastatic sites[20,21]. Peritoneal dissemination of GC is a dynamic multistep process that involves several molecules acting in a coordinated way. As reported in a recent review by Kanda *et al*[22], there are 4 steps in peritoneal dissemination: (1) migration to the abdominal cavity after detachment of cells from the tumor; (2) adaptation to the abdominal microenvironment; (3) adhesion to mesothelial cells and invasion of the baseline membrane; and (4) growth and angiogenesis of the tumor. These molecular mechanisms are very challenging because identification of a single pathway is not necessarily correlated with disease prognosis.

Survival of patients with PC is poor, despite the progress of chemotherapy. Hence, PC is often considered a determinant for a “real” curative treatment possibility, and several scoring systems on extension of PC have been validated to accurately discriminate treatment options, stratify patients prognosis, and, consequently, correct statistical analyses[23-25]. Okabe *et al*[26] noted that in curatively (R0) resected patients, after disappearance of limited peritoneal dissemination treated with induction therapy (S-1 plus cisplatin), MST was significantly longer (43.2 mo) than in patients who underwent non-curative resection (12.6 m), as well as in patients without surgery (10.3 m). To increase chemotherapy efficacy for PC, the literature suggests an additional benefit of hyperthermic intraperitoneal administration of drugs (hyperthermic intraperitoneal chemotherapy, HIPEC)[27-31].

Recent advances in multimodal treatment for patients with peritoneal dissemination are highlighted by Ishigami *et al*[32] in the PHOENIX-GC trial that, although failing to show statistical superiority for intraperitoneal paclitaxel plus systemic chemotherapy, suggested possible clinical benefit for this treatment option. In a systematic review of 10 studies considering 441 patients treated with cytoreductive surgery plus HIPEC, a median overall survival of 15 mo after radical (R0) cytoreduction was shown by Gill *et al*[33]. Consistently, the phase III randomized trial by Yang *et al*[34] and the GYMSSA trial reported improved survival rates with surgery plus HIPEC compared with surgery alone[35].

***Distant metastasis***

Many patients with stage IV GC have multiple metastatic sites. Usually, the first site of metastasis occurring through the hematogenous pathway is the liver. Systemic chemotherapy is a standard treatment approach for GC patients with liver metastases[36], recommended by both the National Comprehensive Cancer Network (NCCN) Guidelines and the Japanese Guidelines[37,38]. Surgical resection has been recently reported to prolong survival in highly selected patients[39-41]. Li *et al*[42] reported a 100% response rate after chemotherapy with weekly DCF regimen before curative gastrectomy in 8 patients. A multidisciplinary approach, including surgery in selected GC patients when the liver is the only site of metastasis, is associated with interesting results[43]. However, treatment of synchronous or metachronous hepatic metastases is not well standardized in GC patients. Once combined with gastrectomy and extended lymphadenectomy, there are no differences in 5-year survival after resection of synchronous and metachronous liver metastases[44]. Considering metachronous metastases, patients submitted to surgery benefit from better selection and exhibit good survival over short and medium terms[45]. Surgical treatment of the best subgroups of candidates can achieve good results that should encourage surgeons and medical oncologists[41,46].

***Lymph node metastases***

A proper lymphadenectomy during surgical resection is a milestone for GC treatment. Patients with para-aortic lymph node (PAN) metastases, or bulky nodes around the hepatic, splenic, or celiac arteries are considered unresectable. Some retrospective studies demonstrated the presence of PAN metastases in greater than 20% of patients undergoing D2 + PAN dissection, and 5-year survival rates of patients with PAN metastases do not exceed 20%[47,48]. Furthermore, a phase III trial JCOG9501 comparing D2 nodal dissection with or without PAN dissection for GC concluded that prophylactic PAN dissection does not improve survival rates[49]. Interestingly, patients with macroscopic metastases in these nodes were excluded from analysis, resulting in a low incidence of metastatic n° 16 nodes in patients receiving PAN dissection. This “selection bias” left open the issue of prognostic efficacy of removal of PAN station in PAN metastatic patients[50]. On the other hand, since 2000, three phase II trials (JCOG0001, JCOG0405 and JCOG1002) have explored preoperative/induction chemotherapy and PAND gastrectomy for bulky N2/N3 gastric cancer[51-54]. The JCOG0001 study reported a low 3-year survival rate (27%) after 2-3 cycles of irinotecan and cisplatin followed by surgery. Conversely, the JCOG0405 trial demonstrated an excellent response rate (up to 64.7%) with 3-year survival of 58.8% in patients who received 2-3 cycles of cisplatin and S-1 before surgery. Similarly, in the JCOG1002 study, among 52 eligible patients, 48 underwent surgery, 44 with R0 resection (84.6%), after 2-3 cycles of docetaxel, cisplatin and S-1 with a pathological response rate of 50%.

**PALLIATIVE CHEMOTHERAPY**

As specified above, according to current guidelines, palliative chemotherapy is the main strategy for treatment of stage IV GC patients. These cases have always represented the ideal setting for use of many new combinations of chemotherapeutic agents, both in Japan and in Western countries[55-67]. The median overall survival observed in these studies varies between 3 and 17 mo. In the SPIRIT trial, an overall survival of 13 mo was reported using S-1 plus cisplatin, which is defined as the standard treatment for metastatic GC in Japan[56]. In Western countries, the treatment most commonly used for metastatic GC is a combination of chemotherapy regimens, including fluoropyrimidine plus a platinum agent, though epirubicin or docetaxel can also be combined[64,66]. Recent developments in chemotherapeutic and molecular targeted agents have added new clinical issues in the management of incurable GC. As reported in the ToGA trial, Trastuzumab plus chemotherapy in HER2-positive patients improved overall median survival from 11.1 to 13.8 mo[60]. In addition, histological biomarkers have been identified to predict survival among GC patients[68]. Recently, palliative chemotherapy seemed further validated compared with palliative surgery by results of the REGATTA trial. In fact, although some authors emphasized the beneficial role of palliative gastrectomy[69,70], in this RCT, Fujitani *et al*[71] demonstrated no survival benefit for palliative gastrectomy prior to chemotherapy in advanced GC patients with a single non-curative factor. However, the methodological biases of the REGATTA trial negatively affect reliability of its results and weaken its potential clinical implications[72]. Therefore, at the moment, for stage IV GC patients, we have no strong evidence to consider the results of palliative chemotherapy satisfactory. On the other hand, we also have no reliable data to suggest definitely abandoning surgery.

**FROM SALVAGE SURGERY TO CONVERSION THERAPY**

The heterogeneous presentation of stage IV GC characteristics makes it difficult to identify the best therapeutic strategy for these tumors due to their different biological behaviors. On the other hand, given the poor results achieved with chemotherapy alone, in order to further improve survival of these patients, new therapeutic approaches have been considered. Based on experiences of the multidisciplinary treatment of metastatic colorectal cancer, in the last 2 decades, many studies have been conducted to evaluate efficacy of the combination of chemotherapy and surgery for stage IV GC. Surgical resection for advanced tumors has historically been called “radical”, “salvage”, “adjuvant” or “secondary” gastrectomy. More specifically, the concept of conversion surgery has been recently treated by Yoshida[17] to define a treatment aiming to R0 resection after chemotherapy in initially unresectable patients.

Tables 1 and 2 show patient characteristics and treatment options analyzed in the considered studies, as well as survival results. Below, we discuss in chronological order the main results of these studies, with particular focus on potential prognostic factors in conversion surgery strategy.

***Examined studies***

Probably, the first report of conversion surgery was in 1997 by Nakajima *et al*[73]. Thirty patients with incurable GC were treated with combined chemotherapy and radical surgery. Survival of patients with curative resection was 55.6% at 5 years. Long-term survivors were exclusively found among patients with distant metastatic lymph nodes. PC and extra-abdominal lesions did not respond to chemotherapy and, hence, did not reach surgery[73].

Yano *et al*[74] analyzed 34 patients with inoperable GC who underwent NAC. Eight patients among 14 who received salvage surgery exhibited curative resection. Histological type, T4 as non-curative factors, clinical response, and salvage surgery were significant prognostic factors. T4 unresectable lesions and para-aortic node metastases showed high dissolution rates after chemotherapy, whereas peritoneal and distant metastases did not[74]. A study on combined treatment with S-1 plus cisplatin followed by gastrectomy and post-operative S-1 for stage IV GC was conducted by Satoh *et al*[75]. Their results showed that 26 patients among 44 who received preoperative chemotherapy underwent R0 surgical resection. Interestingly, all 12 patients with pre-cy1 as a single pre-stage IV factor achieved R0 resection with a 2-year OS of 75%[75].

In 2012, Kanda *et al*[76] reported a good response rate to S-1 chemotherapy in patients with incurable GC who were submitted to secondary surgery. Twenty-six patients of 28 underwent R0 resection. The results showed that 1-, 3-and 5-year survival were 82.1, 45.9 and 34.4%, respectively. Multivariate analysis revealed histological lesion length to be the only significant prognostic factor[76]. According to reports from Han *et al*, 22/34 M1 patients with one initial metastatic site who responded to induction chemotherapy exhibited good survival outcomes after R0 resection, with resection rates of 88% and 44% for one and two metastatic sites, respectively. MST of R0 was 22.9 mo, with a 3-year overall survival of 41.4%[77]. Concerning gastric cancer patients with peritoneal seeding, Kim *et al*[78] published results of 18 conversion patients in which 10 received R0 resection after chemotherapy. MST and 3-year OS of R0 patients were 37 mo and 50%, respectively. Unexpectedly, 8 patients who received non-curative resection had longer survival rates than did other patients who continued chemotherapy[78].

Fukuchi *et al*[79] reported a series of 40 out of 151 patients who underwent conversion surgery. In 32 of them, it was possible to perform R0 resection with a 5-year OS of 49% (MST: 62 mo). By multivariate analysis, the presence of just one non-curative factor and R0 resection were significant independent predictors for good OS[79].

Kinoshita *et al*[80] analyzed the effects of conversion gastrectomy after docetaxel, cisplatin and S-1 (DCS) combined chemotherapy. Of 57 patients, 42 were categorized as unresectable, while 15 patients were potentially resectable cases, with a single incurable factor (16 a2-b1 metastases or < 3 peripheral liver metastases). The 3-year OS rate of potentially resectable cases was 92.9%, compared with 35.1% of unresectable cases[80].

In a multi-institutional retrospective study, Sato *et al*[81] highlighted pathological response as a significant independent predictor for OS. He determined that 33/100 patients were able to undergo conversion therapy. Almost eighty-five of them received an R0 resection after DCS chemotherapy with a pathological response rate of 78.8%. Five-year OS in R0 patients was 48.6%[81].

Ten patients with one incurable factor were retrospectively analyzed by Einama *et al*[82]. All cases were considered resectable after chemotherapy, achieving R0 resection. The authors reported a longer survival of surgical patients compared with those who received chemo alone (MST 29 mo). Non-invasive macroscopic type, higher differentiation, and absence of peritoneal dissemination were all favorable survival predictors[82].

Another study concerning conversion surgery after combination chemotherapy of docetaxel, cisplatin, and S-1 from Mieno *et al*[83] reported that 74.2% of the study population (23/31) underwent R0 resection in patients with stage IV GC initially deemed unresectable. Fifty-eight point one percent of patients had extra regional lymph node as unresectable factor[83].

In a study by Yamaguchi *et al*[84], 84 patients among 259 with stage IV GC received conversion surgery after chemotherapy. Patients were classified into four categories previously published by the same authors[17]. Survival results of this series rose from 24.7 to 31.0 of MST. Patients who underwent R0 resection had an MST of 41.3 mo[84]. Recently, Morgagni *et al*[85] reported a Western series of 22 patients among 73 unresectable subjects who underwent R0 resection after induction chemotherapy. Gastrectomy plus HIPEC was performed in 9 patients. The 1- and 3-year survival rates were 63.6% and 39.4%, respectively[85].

**DISCUSSION**

Gastric cancer is known to be a heterogeneous disease. Dissemination may occur directly to the peritoneum, through the hematogenous and lymphatic systems. Moreover, the method whereby cancer cells enter into the portal circulation varies, resulting in significant variability of metastatic patients both for the site and the amount of tumor. Consequently, few metastatic patients are eligible for conversion surgery. Moreover, frequent coexistence of different factors of incurability make it difficult to identify true prognostic variables, as well as the rate of response to chemotherapeutic treatments. Despite progress in chemotherapy providing significant hope with new drug agents, the response rates of metastatic GC patients remain unsatisfactory with non-optimal patient compliance. The definition of initial unresectable criteria and post-chemotherapy resectability has yet to be established. In many cases, the line between neoadjuvant and induction chemotherapy remains unclear. Therefore, analysis of experiences on conversion surgery in stage IV GC is very challenging due to the heterogeneity of series, makes it very difficult to compare results from different studies. Furthermore, the majority of analyzed studies have been performed in Eastern Asia (only one in Italy). As such, this could represent a potential bias for reliable evaluation independent of differences in chemotherapy schedules, quality of surgery, and patient biology, for example. Undoubtedly, the Regatta trial taught us that even a palliative gastrectomy increases patient morbidity compared with chemotherapy alone. Hence, a strict selection of patients who could potentially benefit from conversion surgery seems mandatory. Yoshida *et al*[17] proposed a biological classification to stratify all stage IV GC patients to respond to this need (Figure 1). Probably, long-term survivors can be found mostly in the first three categories, though the small number of patients in the first category can be explained by this unusual condition. Actually, these patients are likely to benefit from NAC.

Although analyzed studies were retrospective and limited with respect to number of patients enrolled, the possibility of curative resection seems a crucial aspect. The literature reports R0 resection rates ranging from 24%-100% (Table 1), and these numbers are closely correlated with prognosis (Table 2). Thus, the survival benefit derived from R0 resections might justify a predictable increase in morbidity compared with survival from medical therapy alone. Interestingly, even non-curative resection often results in superior survival compared to chemotherapy alone. Consistent with this suggestion from the literature, quality of life (QOL) after conversion (even if non curative) surgery remains an intriguing issue to be analyzed. In this regard, a meta-analysis conducted by Lasithiotakis *et al*[86] underlined the relevant role of QOL outcomes after palliative gastrectomy.

Consistent with considerations by Yoshida *et al*[17], the presence of only one-site of metastasis is one of the most important prognostic factors according to most analyzed studies. In this literature review, lymph node metastases and positive cytology on peritoneal washing as unresectable factors are also related to better prognoses after conversion surgery when partial or complete response to chemo was observed. In this regard, while the more reliable (and later) evaluation of pathological response was demonstrated to be correlated with survival after conversion therapy, we have no unquestionable prognostic data and no objective criteria for clinical response assessment. Indeed, another determining factor is the detection of the best timing to operate (or to decide to not operate). Generally, surgery occurs when the tumor decreases in sizes and before it develops any drug resistance. For this determinant decision making step, cooperation between oncologists and surgeons is mandatory for general management of patients (and not the tumor alone). Regarding type of surgery and extension of lymphadenectomy, total or distal gastrectomy (also with multivisceral approach) aiming at R0 resection was generally associated with D2 or more extended lymphadenectomy. We believe that a proper and standardized D2 lymphadenectomy could achieve optimal results with acceptable morbidity/mortality. Finally, whether chemotherapy is required after an R0 resection is an issue that needs clarification.

In conclusion, the survival efficacy of conversion surgery may dramatically improve when combined with targeted chemotherapy. Perhaps new cytotoxic and molecular targeted agents and progress in sensitive molecular biomarker development could shift treatment from standardized to personalized, leading to further improved outcomes. The promising results of this multimodal therapy are increasingly gaining the attention of medical and surgical oncologists in planning further studies. Although it seems hard to design a valuable trial due to the difficulty of enrolling patients, it appears mandatory to demonstrate the effectiveness of this strategy in stage IV GC patients, or at least in well-selected and stratified stage IV patient subgroups. On the other hand, given that long-time survivors exist, we are convinced that the multidisciplinary discussion should always be recommended on a case-by-case basis. In conclusion, it is well known that some decades ago patients affected by unresectable GC represented a large population on whom medical oncologists applied new and promising therapies without great success. Today, the strategy of conversion surgery induces oncologists to consider that surgery could still have a role, even after almost “hopeless” systemic therapy.

**REFERENCES**

1 **Ferlay J**, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; **136**: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]

2 **Cunningham D**, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006; **355**: 11-20 [PMID: 16822992 DOI: 10.1056/NEJMoa055531]

3 **Ychou M**, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. *J Clin Oncol* 2011; **29**: 1715-1721 [PMID: 21444866 DOI: 10.1200/JCO.2010.33.0597]

4 **Japanese Gastric Cancer Association**. Japanese gastric cancer treatment guidelines 2014 (ver. 4). *Gastric Cancer* 2017; **20**: 1-19 [PMID: 27342689 DOI: 10.1007/s10120-016-0622-4]

5 **Lee JH**, Kim JG, Jung HK, Kim JH, Jeong WK, Jeon TJ, Kim JM, Kim YI, Ryu KW, Kong SH, Kim HI, Jung HY, Kim YS, Zang DY, Cho JY, Park JO, Lim DH, Jung ES, Ahn HS, Kim HJ. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. *J Gastric Cancer* 2014; **14**: 87-104 [PMID: 25061536 DOI: 10.5230/jgc.2014.14.2.87]

6 **Allum WH**, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, the British Society of Gastroenterology and the British Association of Surgical Oncology. Guidelines for the management of oesophageal and gastric cancer. *Gut* 2011; **60**: 1449-1472 [PMID: 21705456 DOI: 10.1136/gut.2010.228254]

7 **Meyer HJ**, Hölscher AH, Lordick F, Messmann H, Mönig S, Schumacher C, Stahl M, Wilke H, Möhler M. [Current S3 guidelines on surgical treatment of gastric carcinoma]. *Chirurg* 2012; **83**: 31-37 [PMID: 22127381 DOI: 10.1007/s00104-011-2149-x]

8 **Waddell T**, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; European Society for Medical Oncology (ESMO); European Society of Surgical Oncology (ESSO); European Society of Radiotherapy and Oncology (ESTRO). Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2013; **24** Suppl 6: vi57-vi63 [PMID: 24078663 DOI: 10.1093/annonc/mdt344]

9 **Ajani JA**, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TK Jr, Warren G, Washington MK, Willett C, Wright CD, McMillian NR, Sundar H; National Comprehensive Cancer Network. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. *J Natl Compr Canc Netw* 2013; **11**: 531-546 [PMID: 23667204 DOI: 10.6004/jnccn.2013.0070]

10 **Howlader N**, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2008. National Cancer Institute, Bethesda, MD, 2011. Available from: URL: https://seer.cancer.gov/csr/1975\_2008/

11 **Sano T**, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. *Gastric Cancer* 2011; **14**: 97-100 [PMID: 21573921 DOI: 10.1007/s10120-011-0040-6]

12 **Union for International Cancer Control (UICC)**. TNM Classification of Malignant Tumours. 8th edition. Wiley-Blackwell, 2016

13 **Japanese Gastric Cancer Association**. Japanese classification of gastric carcinoma: 3rd English edition. *Gastric Cancer* 2011; **14**: 101-112 [PMID: 21573743 DOI: 10.1007/s10120-011-0041-5]

14 **Hermanek P**. The second English edition of the Japanese Classification of Gastric Carcinoma. A Western commentary. *Gastric Cancer* 1999; **2**: 79-82 [PMID: 11957076 DOI: 10.1007/s101209900032]

15 **Sasako M**, Aiko T. Reply to Professor Hermanek's comments on the new Japanese classification of gastric carcinoma. *Gastric Cancer* 1999; **2**: 83-85 [PMID: 11957077 DOI: 10.1007/s101209900033]

16 **Zurleni T**, Gjoni E, Ballabio A, Casieri R, Ceriani P, Marzoli L, Zurleni F. Sixth and seventh tumor-node-metastasis staging system compared in gastric cancer patients. *World J Gastrointest Surg* 2013; **5**: 287-293 [PMID: 24520426 DOI: 10.4240/wjgs.v5.i11.287]

17 **Yoshida K**, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. *Gastric Cancer* 2016; **19**: 329-338 [PMID: 26643880 DOI: 10.1007/s10120-015-0575-z]

18 **Thomassen I**, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE, de Hingh IH. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. *Int J Cancer* 2014; **134**: 622-628 [PMID: 23832847 DOI: 10.1002/ijc.28373]

19 **Abbasi SY**, Taani HE, Saad A, Badheeb A, Addasi A. Advanced gastric cancer in jordan from 2004 to 2008: a study of epidemiology and outcomes. *Gastrointest Cancer Res* 2011; **4**: 122-127 [PMID: 22368735]

20 **Chau I**, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. *J Clin Oncol* 2004; **22**: 2395-2403 [PMID: 15197201 DOI: 10.1200/JCO.2004.08.154]

21 **Kim JG**, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, Kang YK. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. *Cancer Chemother Pharmacol* 2008; **61**: 301-307 [PMID: 17429626 DOI: 10.1007/s00280-007-0476-x]

22 **Kanda M**, Kodera Y. Molecular mechanisms of peritoneal dissemination in gastric cancer. *World J Gastroenterol* 2016; **22**: 6829-6840 [PMID: 27570420 DOI: 10.3748/wjg.v22.i30.6829]

23 **Sugarbaker TA**, Chang D, Koslowe P, Sugarbaker PH. Patterns of spread of recurrent intraabdominal sarcoma. *Cancer Treat Res* 1996; **82**: 65-77 [PMID: 8849944 DOI: 10.1007/978-1-4613-1247-5\_5]

24 **Gilly FN**, Carry PY, Sayag AC, Brachet A, Panteix G, Salle B, Bienvenu J, Burgard G, Guibert B, Banssillon V. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. *Hepatogastroenterology* 1994; **41**: 124-129 [PMID: 8056398]

25 **Japanese research Society for Gastric Cancer**. The general rules for the gastric cancer study in surgery and pathology. 12th ed. Tokyo: Kanehara Shuppan, 1993

26 **Okabe H**, Ueda S, Obama K, Hosogi H, Sakai Y. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. *Ann Surg Oncol* 2009; **16**: 3227-3236 [PMID: 19777180 DOI: 10.1245/s10434-009-0706-z]

27 **Fujimoto S**, Shrestha RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, Kiuchi S, Okui K, Miyoshi T, Arimizu N. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. *Ann Surg* 1988; **208**: 36-41 [PMID: 3133994 DOI: 10.1097/00000658-198807000-00005]

28 **Yonemura Y**, Fujimura T, Nishimura G, FallaR, Sawa T, Katayama K, Tsugawa K, Fushida S, Miyazaki I, Tanaka M, Endou Y, Sasaki T. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination. *Surgery* 1996; **119**: 437-444 [PMID: 8644010 DOI: 10.1016/S0039-6060(96)80145-0]

29 **Glehen O**, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D; Association Française de Chirurgie. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. *Ann Surg Oncol* 2010; **17**: 2370-2377 [PMID: 20336386 DOI: 10.1245/s10434-010-1039-7]

30 **Hall JJ**, Loggie BW, Shen P, Beamer S, Douglas Case L, McQuellon R, Geisinger KR, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. *J Gastrointest Surg* 2004; **8**: 454-463 [PMID: 15120371 DOI: 10.1016/j.gassur.2003.12.014]

31 **Yang XJ**, Li Y, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center. *J Surg Oncol* 2010; **101**: 457-464 [PMID: 20401915 DOI: 10.1002/jso.21519]

32 **Ishigami H**, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Miyaji T, Kitayama J. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial. *J Clin Oncol* 2018; **36**: 1922-1929 [PMID: 29746229 DOI: 10.1200/JCO.2018.77.8613]

33 **Gill RS**, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, Schiller D. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. *J Surg Oncol* 2011; **104**: 692-698 [PMID: 21713780 DOI: 10.1002/jso.22017]

34 **Yang XJ**, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. *Ann Surg Oncol* 2011; **18**: 1575-1581 [PMID: 21431408 DOI: 10.1245/s10434-011-1631-5]

35 **Rudloff U**, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. *J Surg Oncol* 2014; **110**: 275-284 [PMID: 25042700 DOI: 10.1002/jso.23633]

36 **Boku N**, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. *Lancet Oncol* 2009; **10**: 1063-1069 [PMID: 19818685 DOI: 10.1016/S1470-2045(09)70259-1]

37 **Ajani JA**, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G; NCCN Gastric Cancer Panel. Gastric cancer. *J Natl Compr Canc Netw* 2010; **8**: 378-409 [PMID: 20410333]

38 **Japanese Gastric Cancer Association**. Japanese gastric cancer treatment guidelines 2010 (ver. 3). *Gastric Cancer* 2011; **14**: 113-123 [PMID: 21573742 DOI: 10.1007/s10120-011-0042-4]

39 **Cheon SH**, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, Ahn JB, Roh JK, Noh SH, Chung HC. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. *Ann Oncol* 2008; **19**: 1146-1153 [PMID: 18304963 DOI: 10.1093/annonc/mdn026]

40 **Sakamoto Y**, Sano T, Shimada K, Esaki M, Saka M, Fukagawa T, Katai H, Kosuge T, Sasako M. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. *J Surg Oncol* 2007; **95**: 534-539 [PMID: 17219383 DOI: 10.1002/jso.20739]

41 **Takemura N**, Saiura A, Koga R, Arita J, Yoshioka R, Ono Y, Hiki N, Sano T, Yamamoto J, Kokudo N, Yamaguchi T. Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. *Langenbecks Arch Surg* 2012; **397**: 951-957 [PMID: 22615045 DOI: 10.1007/s00423-012-0959-z]

42 **Li ZY**, Tang L, Zhang LH, Bu ZD, Wu AW, Wu XJ, Zong XL, Wu Q, Shan F, Li SX, Ren H, Zhang XP, Ji JF. Weekly docetaxel and cisplatin plus fluorouracil as a preoperative treatment for gastric cancer patients with synchronous multiple hepatic metastases: a pilot study. *Med Oncol* 2010; **27**: 1314-1318 [PMID: 19967569 DOI: 10.1007/s12032-009-9381-y]

43 **Gadde R**, Tamariz L, Hanna M, Avisar E, Livingstone A, Franceschi D, Yakoub D. Metastatic gastric cancer (MGC) patients: Can we improve survival by metastasectomy? A systematic review and meta-analysis. *J Surg Oncol* 2015; **112**: 38-45 [PMID: 26074130 DOI: 10.1002/jso.23945]

44 **Markar SR**, Mikhail S, Malietzis G, Athanasiou T, Mariette C, Sasako M, Hanna GB. Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: Systematic Review and Pooled Analysis. *Ann Surg* 2016; **263**: 1092-1101 [PMID: 26797324 DOI: 10.1097/SLA.0000000000001542]

45 **Tiberio GA**, Ministrini S, Gardini A, Marrelli D, Marchet A, Cipollari C, Graziosi L, Pedrazzani C, Baiocchi GL, La Barba G, Roviello F, Donini A, de Manzoni G; Italian Research Group for Gastric Cancer. Factors influencing survival after hepatectomy for metastases from gastric cancer. *Eur J Surg Oncol* 2016; **42**: 1229-1235 [PMID: 27134189 DOI: 10.1016/j.ejso.2016.03.030]

46 **Schildberg CW**, Croner R, Merkel S, Schellerer V, Müller V, Yedibela S, Hohenberger W, Peros G, Perrakis A. Outcome of operative therapy of hepatic metastatic stomach carcinoma: a retrospective analysis. *World J Surg* 2012; **36**: 872-878 [PMID: 22354489 DOI: 10.1007/s00268-012-1492-5]

47 **Kunisaki C**, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono H, Nagahori Y, Hosoi H, Takahashi M, Kito F, Shimada H. Comparison of surgical results of D2 versus D3 gastrectomy (para-aortic lymph node dissection) for advanced gastric carcinoma: a multi-institutional study. *Ann Surg Oncol* 2006; **13**: 659-667 [PMID: 16538414 DOI: 10.1245/ASO.2006.07.015]

48 **Fujimura T**, Nakamura K, Oyama K, Funaki H, Fujita H, Kinami S, Ninomiya I, Fushida S, Nishimura G, Kayahara M, Ohta T. Selective lymphadenectomy of para-aortic lymph nodes for advanced gastric cancer. *Oncol Rep* 2009; **22**: 509-514 [PMID: 19639196 DOI: 10.3892/or\_00000464]

49 **Sasako M**, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y, Okajima K; Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. *N Engl J Med* 2008; **359**: 453-462 [PMID: 18669424 DOI: 10.1056/NEJMoa0707035]

50 **Roviello F**, Pedrazzani C, Marrelli D, Di Leo A, Caruso S, Giacopuzzi S, Corso G, de Manzoni G. Super-extended (D3) lymphadenectomy in advanced gastric cancer. *Eur J Surg Oncol* 2010; **36**: 439-446 [PMID: 20392590 DOI: 10.1016/j.ejso.2010.03.008]

51 **Yoshikawa T**, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, Oshita H, Ito S, Kawashima Y, Fukushima N. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. *Br J Surg* 2009; **96**: 1015-1022 [PMID: 19644974 DOI: 10.1002/bjs.6665]

52 **Tsuburaya A**, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. *Br J Surg* 2014; **101**: 653-660 [PMID: 24668391 DOI: 10.1002/bjs.9484]

53 **Katayama H**, Ito S, Sano T, Takahari D, Mizusawa J, Boku N, Tsuburaya A, Terashima M, Sasako M; Stomach Cancer Study Group of the Japan Clinical Oncology Group. A Phase II study of systemic chemotherapy with docetaxel, cisplatin, and S-1 (DCS) followed by surgery in gastric cancer patients with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1002. *Jpn J Clin Oncol* 2012; **42**: 556-559 [PMID: 22525210 DOI: 10.1093/jjco/hys054]

54 **Ito S**, Sano T, Mizusawa J, Takahari D, Katayama H, Katai H, Kawashima Y, Kinoshita T, Terashima M, Nashimoto A, Nakamori M, Onaya H, Sasako M. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. *Gastric Cancer* 2017; **20**: 322-331 [PMID: 27299887 DOI: 10.1007/s10120-016-0619-z]

55 **Takashima A**, Boku N, Kato K, Nakamura K, Mizusawa J, Fukuda H, Shirao K, Shimada Y, Ohtsu A. Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912. *Gastric Cancer* 2014; **17**: 522-528 [PMID: 24162387 DOI: 10.1007/s10120-013-0309-z]

56 **Koizumi W**, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. *Lancet Oncol* 2008; **9**: 215-221 [PMID: 18282805 DOI: 10.1016/S1470-2045(08)70035-4]

57 **Koizumi W**, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, Hosaka H, Tsuji A, Takagane A, Inokuchi M, Tanabe K, Okuno T, Ogura M, Yoshida K, Takeuchi M, Nakajima T; JACCRO and KCSG Study Group. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). *J Cancer Res Clin Oncol* 2014; **140**: 319-328 [PMID: 24366758 DOI: 10.1007/s00432-013-1563-5]

58 **Ryu MH**, Baba E, Lee KH, Boku N, Park YI, Hyodo I. Phase III trial of a 3-weekly versus 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study. *J Clin Oncol* 2013; **31**: LBA4024 [DOI: 10.1093/annonc/mdv316]

59 **Yamada Y**, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. *Ann Oncol* 2015; **26**: 141-148 [PMID: 25316259 DOI: 10.1093/annonc/mdu472]

60 **Bang YJ**, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; **376**: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]

61 **Ohtsu A**, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. *J Clin Oncol* 2011; **29**: 3968-3976 [PMID: 21844504 DOI: 10.1200/JCO.2011.36.2236]

62 **Vanhoefer U**, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. *J Clin Oncol* 2000; **18**: 2648-2657 [PMID: 10894863 DOI: 10.1200/JCO.2000.18.14.2648]

63 **Ajani JA**, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha R, Carrato A, Ferry D, Moiseyenko V. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. *Eur J Cancer* 2013; **49**: 3616-3624 [PMID: 23899532 DOI: 10.1016/j.ejca.2013.07.003]

64 **Van Cutsem E**, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *J Clin Oncol* 2006; **24**: 4991-4997 [PMID: 17075117 DOI: 10.1200/JCO.2006.06.8429]

65 **Dank M**, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. *Ann Oncol* 2008; **19**: 1450-1457 [PMID: 18558665 DOI: 10.1093/annonc/mdn166]

66 **Cunningham D**, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med* 2008; **358**: 36-46 [PMID: 18172173 DOI: 10.1056/NEJMoa073149]

67 **Kang YK**, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. *Ann Oncol* 2009; **20**: 666-673 [PMID: 19153121 DOI: 10.1093/annonc/mdn717]

68 **Sekikawa A**, Fukui H, Zhang X, Maruo T, Tsumura T, Okabe Y, Wakasa T, Osaki Y, Chiba T, Tomita T, Oshima T, Watari J, Miwa H. REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer. *Br J Cancer* 2013; **108**: 395-401 [PMID: 23322208 DOI: 10.1038/bjc.2012.572]

69 **Hartgrink HH**, Putter H, Klein Kranenbarg E, Bonenkamp JJ, van de Velde CJ; Dutch Gastric Cancer Group. Value of palliative resection in gastric cancer. *Br J Surg* 2002; **89**: 1438-1443 [PMID: 12390389 DOI: 10.1046/j.1365-2168.2002.02220.x]

70 **Sun J**, Song Y, Wang Z, Chen X, Gao P, Xu Y, Zhou B, Xu H. Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. *BMC Cancer* 2013; **13**: 577 [PMID: 24304886 DOI: 10.1186/1471-2407-13-577]

71 **Fujitani K**, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T, Hahn S, Nakamura K, Park CH, Kurokawa Y, Bang YJ, Park BJ, Sasako M, Tsujinaka T; REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. *Lancet Oncol* 2016; **17**: 309-318 [PMID: 26822397 DOI: 10.1016/S1470-2045(15)00553-7]

72 **D'Ugo D**, Cananzi FC, Persiani R, Agnes A, Biondi A. REGATTA trial: a call for the USA and Europe. *Lancet Oncol* 2016; **17**: 261-262 [PMID: 26972851 DOI: 10.1016/S1470-2045(15)00619-1]

73 **Nakajima T**, Ota K, Ishihara S, Oyama S, Nishi M, Ohashi Y, Yanagisawa A. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. *Ann Surg Oncol* 1997; **4**: 203-208 [PMID: 9142380 DOI: 10.1007/BF02306611]

74 **Yano M**, Shiozaki H, Inoue M, Tamura S, Doki Y, Yasuda T, Fujiwara Y, Tsujinaka T, Monden M. Neoadjuvant chemotherapy followed by salvage surgery: effect on survival of patients with primary noncurative gastric cancer. *World J Surg* 2002; **26**: 1155-1159 [PMID: 12209246 DOI: 10.1007/s00268-002-6362-0]

75 **Satoh S**, Okabe H, Teramukai S, Hasegawa S, Ozaki N, Ueda S, Tsuji A, Sakabayashi S, Fukushima M, Sakai Y. Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer. *Gastric Cancer* 2012; **15**: 61-69 [PMID: 21667134 DOI: 10.1007/s10120-011-0066-9]

76 **Kanda T**, Yajima K, Kosugi S, Ishikawa T, Ajioka Y, Hatakeyama K. Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective study. *Gastric Cancer* 2012; **15**: 235-244 [PMID: 22033890 DOI: 10.1007/s10120-011-0100-y]

77 **Han DS**, Suh YS, Kong SH, Lee HJ, Im SA, Bang YJ, Kim WH, Yang HK. Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases. *J Surg Oncol* 2013; **107**: 511-516 [PMID: 23090791 DOI: 10.1002/jso.23284.]

78 **Kim SW**. The result of conversion surgery in gastric cancer patients with peritoneal seeding. *J Gastric Cancer* 2014; **14**: 266-270 [PMID: 25580359 DOI: 10.5230/jgc.2014.14.4.266]

79 **Fukuchi M**, Ishiguro T, Ogata K, Suzuki O, Kumagai Y, Ishibashi K, Ishida H, Kuwano H, Mochiki E. Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer. *Ann Surg Oncol* 2015; **22**: 3618-3624 [PMID: 25663597 DOI: 10.1245/s10434-015-4422-6]

80 **Kinoshita J**, Fushida S, Tsukada T, Oyama K, Okamoto K, Makino I, Nakamura K, Miyashita T, Tajima H, Takamura H, Ninomiya I, Ohta T. Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer. *Eur J Surg Oncol* 2015; **41**: 1354-1360 [PMID: 26028256 DOI: 10.1016/j.ejso.2015.04.021]

81 **Sato Y**, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi M, Maeda M, Okagawa Y, Naoki U, Kikuch S, Okamoto K, Miyamoto H, Shimada M, Takemasa I, Kato J, Takayama T. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. *Gastric Cancer* 2017; **20**: 517-526 [PMID: 27553665 DOI: 10.1007/s10120-016-0633-1]

82 **Einama T**, Abe H, Shichi S, Matsui H, Kanazawa R, Shibuya K, Suzuki T, Matsuzawa F, Hashimoto T, Kohei N, Homma S, Kawamura H, Taketomi A. Long-term survival and prognosis associated with conversion surgery in patients with metastatic gastric cancer. *Mol Clin Oncol* 2017; **6**: 163-166 [PMID: 28357085 DOI: 10.3892/mco.2017.1128]

83 **Mieno H**, Yamashita K, Hosoda K, Moriya H, Higuchi K, Azuma M, Komori S, Yoshida T, Tanabe S, Koizumi W, Katada N, Watanabe M. Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer. *Surg Today* 2017; **47**: 1249-1258 [PMID: 28365892 DOI: 10.1007/s00595-017-1512-z]

84 **Yamaguchi K**, Yoshida K, Tanahashi T, Takahashi T, Matsuhashi N, Tanaka Y, Tanabe K, Ohdan H. The long-term survival of stage IV gastric cancer patients with conversion therapy. *Gastric Cancer* 2018; **21**: 315-323 [PMID: 28616743 DOI: 10.1007/s10120-017-0738-1]

85 **Morgagni P**, Solaini L, Framarini M, Vittimberga G, Gardini A, Tringali D, Valgiusti M, Monti M, Ercolani G. Conversion surgery for gastric cancer: A cohort study from a western center. *Int J Surg* 2018; **53**: 360-365 [PMID: 29654967 DOI: 10.1016/j.ijsu.2018.04.016]

86 **Lasithiotakis K**, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. *Anticancer Res* 2014; **34**: 2079-2085 [PMID: 24778009]

**P-Reviewer:** Arigami T, Barreto SG, Caboclo JF, Fujita T, Ierardi E **S-Editor:** Ji FF **L-Editor: E-Editor:**

**Specialty type:** Oncology

**Country of origin:** Italy

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): E



**Figure 1 Biological categories proposed by Yoshida *et al*[17].** GC: Gastric cancer.

**Table 1 Patient characteristics and onco-surgical treatments**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Period** | **Population (conversion surgery)** | **Median - age** | **Unresectable criteria** | **Chemotherapy** | **Surgery** | **Lymphadenectomy (D2 or more)** | **Ro** |
| **P1** | **H1** | **Cy1** | **PAN/N3** | **T4** | **Other** |
| **Nakajima *et al*[73], 1997**  | 1989-1995 | 30 (19) | 53 | 9 (30%) | 11 (37%) |  | 23 (77%) | 8 (27%) | 3 (10%) | FLEP | NS | NS | 9 (30%) |
| **Yano *et al*[74], 2002**  | May 1994-Dec 1999 | 34 (14) | 54.4 (31-73) | 26 (76%) | 4 (12%) |  | 10 (3.4%) | 12 (35%) | 1 (0.3%) | FEMTXP or THP-FLPM | NS | NS | 8 (24%) |
| **Satoh *et al*[75],2012**  | May 2003-Mar 2008 | 51 (44) | 63 (35-79) | 24 (49%) | 3 (6%) | 12 (23%) | 7 (14%) |  | 5 (10%) | S1 + Cisplatin | TG (58%) DG (21,5%) | 82% | 26 (51%) |
| **Kanda *et al*[76],2012**  | Apr 2000-Mar 2008 | 31(28) | 65,5 (49-79) | 7 (25%) | 4 (14.3) |  | 15 (54%) | 9 (32%) |  | S1 + Cisplatin or Paclitaxel or Irinotecan | TG (42.89) DG (57.1%) | 96.30% | 26 (93%) |
| **Han *et al*[77], 2014**  | Jan 2000-Dec 2009 | 34 (34) | 56 (28-71) | 7 (14%) | 5 (10%) |  | 15 (29.4%) |  | 7 (14%) | 5-FU + Platinum or 5-FU + Platinum + Taxane | NS | NS | 26 (76.5%) |
| **Kim *et al*[78], 2014**  | Jan 2003-Dec 2012 | 43 (18) | 52.8 (32-72) | 43 (100%) |  |  |  |  |  | 5-FU + Cisplatin or S1 + Cisplatin | TG (72.2%) DG (27.7%) | 100% | 10 (55%) |
| **Fukuchi *et al*[79], 2015**  | Feb 2003-Dec 2013 | 151 (40) | 66 (31-79) | 11 (28%) | 5 (13%) | 3 (8%) |  | 6 (15%) | 26 (65%) | S1 + Cisplatin or S1 + Paclitaxel | TG (72.5%) DG (27.5%) | NS | 32 (80%) |
| **Kinoshita *et al*[80], 2015**  | Apr 2006-Mar 2012 | 57 (34) | 65 (30-78) | 15 (26%9 | 18 (32%) |  | 23 (40%) |  | 2 (3.5%) | DCS | TG (64.7%) DG (26.5%) | 50% | 27 (79%) |
| **Sato *et al*[81], 2017**  | Dec 2002-Apr 2014 | 100 (33) | 63 (26-78) | 33 (33%) | 29 (29%) |  | 61 (61%) | 14 (14%) | 11 (11%) | DCS I line, CPT-11 II line | TG (84.8%) DG (12.1%) | 100% | 28 (85%) |
| **Einama *et al*[82],2017**  | Jan 2009-Dec 2015 | 10 | 70.5 (59-86) | 3 (30%) | 1 (10%) | 1 (10%) | 4 (40%) | 1 (10%) |  | S1 + CDDP or DOC | TG (40%) DG (30%) | 100% | 10 (100%) |
| **Mieno *et al*[83],2017**  | Oct 2006-Dec 2012 | 31 (31) | 63 (35-78) | 25% | 16% |  | 58% | 26% |  | DCS + DS (Docetaxel-S1) in responder patients | TG (74.2%) DG (22.6%) | 77% | 23 (74%) |
| **Yamaguchi *et al*[84], 2017**  | 2001-2013 | 259 (84) | 61.7 (21-78) | 35 (41%) |  |  | 37 (44%) |  | 34 (40%) | DCS or S1 or S1 + Cisplatin or S1 + Taxane | TG (82.1%) DG (17.9%) | NS | 43 (51%) |
| **Morgagni *et al*[85], 2018**  | Apr 2005-Aug 2016 | 73 (22) | 69 (59-74) |  |  |  |  |  |  | Epirubicin + Cisplatinum + 5FU or Oxaliplatin + 5FU or Docetaxel + Oxaliplatin + 5FU or Other | TG (72.7%) DG (22.7%) | 91.90% | 22 (100%) |

P1: Peritoneal carcinomatosis; H1: Hepatic metastases; Cy1: Positive cytology; PAN: Para-aortic node metastases; TG: Total gastrectomy; DG: Distal gastrectomy; DCS/DS: Docetaxel-Cisplatin-S1/Docetaxel-Cisplatin; FEMTXP: Fluorouracil, epirubicin, methotrexate, cisplatin; THP-FLPM: Pirarubicin, 5-FU, Leucovorin, Cisplatin, mitomycin C; FLEP: 5-FU + Leucovorin + Etoposide; CDDP: Cisplatin; DOC: Docetaxel; NS: Not specified.

**Table 2 Overall survival and median survival time**

|  |  |  |  |
| --- | --- | --- | --- |
| **Reference** | **Years** | **OS (rate)** | **MST (mo)** |
| **CHT** | **CHT + surgery** | **CHT** | **CHT + surgery** |
|  | **R1/R2** | **R0** |  | **R1/R2** | **R0** |
| **Nakajima *et al*[73], 1997**  | 2/3-yr |  |  |  | 4.7 | 6.5 |  |
| 5-yr |  |  | 55.6 |
| **Yano *et al*[74], 20022**  | 2/3-yr |  |  |  |  |  |  |
| 5-yr |  |  |  |
| **Satoh *et al*[75], 2012**  | 2/3-yr |  | 43 | 751 |  |  | 19.2 |
| 5-yr |  |  |  |
| **Kanda *et al*[76], 2012**  | 2/3-yr |  | 0 | 45.9 |  |  | 29 |
| 5-yr |  |  | 34.4 |
| **Han *et al*[77], 2014**  | 2/3-yr |  |  | 41.4 |  | 7.8 | 22.9 |
| 5-yr |  |  |  |
| **Kim *et al*[78], 2014**  | 2/3-yr | 0 | 0 | 50 | 8 | 18 | 37 |
| 5-yr |  |  |  |
| **Fukuchi *et al*[79], 2015** | 2/3-yr |  |  |  | 14 | 30 | 62 |
| 5-yr | 1 | 15 | 49 |
| **Kinoshita *et al*[80], 2015**  | 2/3-yr | 0 | 16 | 63.5 | 9.6 | 29.9 |  |
| 5-yr |  |  |  |
| **Sato *et al*[81], 2017**  | 2/3-yr | 18.7 |  |  | 15.7 | 21.7 | 47.9 |
| 5-yr | 0 | 0 | 48.6 |
| **Einama *et al*[82], 2017**  | 2/3-yr |  |  |  |  |  | 29 |
| 5-yr |  |  |  |
| **Mieno *et al*[83], 2017**  | 2/3-yr | 56.9 |  | 73.1 |  | 56.1 |  |
| 5-yr |  |  |  |
| **Yamaguchi *et al*[84], 2017**  | 2/3-yr |  |  |  | 11.3 | 21.2 | 41.3 |
| 5-yr |  |  |  |
| **Morgagni *et al*[85], 2018**  | 2/3 yr | 0 |  | 39.4 | 14 |  | 383 |
| 5 yr |  |  |  |

1R0 in only pre-Cy1 patients; **2**No data are specified but a *P* value < 0.0003 is shown between resected and not-resected 5-years OS rate; 3Patients who had cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy had an MST of 50 mo. OS: Overall survival; MST: Median survival time; CHT: Chemotherapy.